{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:34:46Z","timestamp":1782862486258,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","award":["316997"],"award-info":[{"award-number":["316997"]}],"id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40263-020-00730-8","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T11:03:02Z","timestamp":1587466982000},"page":"651-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands"],"prefix":"10.1007","volume":"34","author":[{"given":"Harmen","family":"Beurmanjer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Luykx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"De Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"van Rompaey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. J. A.","family":"Buwalda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A. J.","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. A. G.","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F. A.","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"issue":"1","key":"730_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2165\/00139709-200423010-00005","volume":"23","author":"AF Tarabar","year":"2004","unstructured":"Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev. 2004;23(1):45\u20139.","journal-title":"Toxicol Rev."},{"key":"730_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0028-3908(64)90074-7","volume":"3","author":"H Laborit","year":"1964","unstructured":"Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol. 1964;3:433\u201351.","journal-title":"Int J Neuropharmacol."},{"issue":"2","key":"730_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.1360-0443.2003.00265.x","volume":"98","author":"L Degenhardt","year":"2003","unstructured":"Degenhardt L, Darke S, Dillon P. The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction. 2003;98(2):199\u2013204.","journal-title":"Addiction"},{"issue":"9","key":"730_CR4","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3109\/15563650.2015.1088157","volume":"53","author":"AM Dines","year":"2015","unstructured":"Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12\u00a0months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2015;53(9):893\u2013900.","journal-title":"Clin Toxicol"},{"issue":"4","key":"730_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.sleep.2009.01.005","volume":"10","author":"DL Zvosec","year":"2009","unstructured":"Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med. 2009;10(4):490\u20133.","journal-title":"Sleep Med"},{"issue":"1","key":"730_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40263-016-0402-z","volume":"31","author":"RM Kamal","year":"2017","unstructured":"Kamal RM, van Noorden MS, Wannet W, Beurmanjer H, Dijkstra BAG, Schellekens A. Pharmacological treatment in gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs. 2017;31(1):51\u201364.","journal-title":"CNS Drugs"},{"issue":"1","key":"730_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1570159X13666141210215423","volume":"13","author":"F Busardo","year":"2015","unstructured":"Busardo F, Jones A. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13(1):47\u201370.","journal-title":"Curr Neuropharmacol"},{"key":"730_CR8","doi-asserted-by":"publisher","DOI":"10.1159\/000500807","author":"H Beurmanjer","year":"2019","unstructured":"Beurmanjer H, Asperslag EM, Oliemeulen L, Goudriaan AE, De Jong CAJ, Schellekens ASA, et al. A qualitative approach in understanding illness perception and treatment needs in patients with gamma hydroxybutyrate use disorder. Eur Addict Res. 2019. https:\/\/doi.org\/10.1159\/000500807.","journal-title":"Eur Addict Res"},{"key":"730_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neubiorev.2015.03.012","volume":"53","author":"JM Corkery","year":"2015","unstructured":"Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev. 2015;53:52\u201378. https:\/\/doi.org\/10.1016\/j.neubiorev.2015.03.012.","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"730_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/105504901750532111","volume":"10","author":"K Miotto","year":"2001","unstructured":"Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict. 2001;10(3):232\u201341.","journal-title":"Am J Addict."},{"key":"730_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fncel.2019.00163","volume":"13","author":"JM Lorenz-Guertin","year":"2019","unstructured":"Lorenz-Guertin JM, Bambino MJ, Das S, Weintraub ST, Jacob TC. Diazepam accelerates GABAAR synaptic exchange and alters intracellular trafficking. Front Cell Neurosci. 2019;13:163. https:\/\/doi.org\/10.3389\/fncel.2019.00163.","journal-title":"Front Cell Neurosci."},{"issue":"4","key":"730_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.psym.2014.03.002","volume":"56","author":"MS van Noorden","year":"2015","unstructured":"van Noorden MS, Kamal RM, Dijkstra BAG, Mauritz R, de Jong CAJ. A case series of pharmaceutical gamma-hydroxybutyrate in 3 patients with severe benzodiazepine-resistant gamma-hydroxybutyrate withdrawal in the hospital. Psychosomatics. 2015;56(4):404\u20139.","journal-title":"Psychosomatics."},{"issue":"1","key":"730_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0736-4679(99)00163-8","volume":"18","author":"K Craig","year":"2000","unstructured":"Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med. 2000;18(1):65\u201370.","journal-title":"J Emerg Med"},{"issue":"5","key":"730_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00115-018-0636-8","volume":"90","author":"P Neu","year":"2019","unstructured":"Neu P. Course and complications of GHB detoxification treatment: a 1-year case series [in German]. Nervenarzt. 2019;90(5):509\u201315. https:\/\/doi.org\/10.1007\/s00115-018-0636-8.","journal-title":"Nervenarzt."},{"issue":"6","key":"730_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1067\/mem.2001.119454","volume":"38","author":"MLA Sivilotti","year":"2001","unstructured":"Sivilotti MLA, Burns MJ, Aaron CK, Greenberg MJ. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med. 2001;38(6):660\u20135.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"730_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1067\/mem.2001.112985","volume":"37","author":"JE Dyer","year":"2001","unstructured":"Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med. 2001;37(2):147\u201353.","journal-title":"Ann Emerg Med"},{"key":"730_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.drugalcdep.2016.11.014","volume":"170","author":"BAG Dijkstra","year":"2017","unstructured":"Dijkstra BAG, Kamal R, van Noorden MS, de Haan H, Loonen AJM, De Jong CAJ. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: the Dutch GHB monitor project. Drug Alcohol Depend. 2017;170:164\u201373.","journal-title":"Drug Alcohol Depend"},{"key":"730_CR18","volume-title":"Treatment of patients with GHB dependence: end report of the GHB Monitor 2.0 [in Dutch]","author":"H Beurmanjer","year":"2016","unstructured":"Beurmanjer H, Verbrugge CAG, Schrijen SSA, DeJong CAJ DB. Treatment of patients with GHB dependence: end report of the GHB Monitor 2.0 [in Dutch]. Nijmegen: NISPA; 2016."},{"key":"730_CR19","doi-asserted-by":"publisher","unstructured":"Kwako LE, Koob GF. Neuroclinical framework for the role of stress in addiction. Chronic Stress (Thousand Oaks). 2017 Feb; 1: https:\/\/doi.org\/10.1177\/2470547017698140. https:\/\/doi.org\/10.1177\/2470547017698140.","DOI":"10.1177\/2470547017698140 10.1177\/2470547017698140"},{"issue":"5","key":"730_CR20","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1360-0443.2009.02889.x","volume":"105","author":"GM Schippers","year":"2010","unstructured":"Schippers GM, Broekman TG, Buchholz A, Koeter MWJ, Van Den Brink W. Measurements in the Addictions for Triage and Evaluation (MATE): an instrument based on the World Health Organization family of international classifications. Addiction. 2010;105(5):862\u201371.","journal-title":"Addiction"},{"issue":"3","key":"730_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/00952998709001515","volume":"13","author":"L Handelsman","year":"1987","unstructured":"Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293\u2013308.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"10","key":"730_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/add.13868","volume":"112","author":"JM Schmitz","year":"2017","unstructured":"Schmitz JM, Green CE, Hasan KM, Vincent J, Suchting R, Weaver MF, et al. PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial. Addiction. 2017;112(10):1861\u20138.","journal-title":"Addiction"},{"key":"730_CR23","unstructured":"Strand NAW, Petersen TS, Nielsen LM, Boegevig S. Treatment of gamma-hydroxybutyrate withdrawal [in Danish]. Ugeskr Laeger. 2017;179(50)."},{"issue":"12","key":"730_CR24","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s00134-015-4063-z","volume":"41","author":"IJ Zaal","year":"2015","unstructured":"Zaal IJ, Devlin JW, Hazelbag M, Klein Klouwenberg PMC, van der Kooi AW, Ong DSY, et al. Benzodiazepine-associated delirium in critically ill adults. Intensive Care Med. 2015;41(12):2130\u20137. https:\/\/doi.org\/10.1007\/s00134-015-4063-z.","journal-title":"Intensive Care Med"},{"issue":"1","key":"730_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0736-4679(01)00324-9","volume":"21","author":"AB Schneir","year":"2001","unstructured":"Schneir AB, Ly BT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med. 2001;21(1):31\u20133.","journal-title":"J Emerg Med"},{"issue":"5","key":"730_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40263-018-0516-6","volume":"32","author":"H Beurmanjer","year":"2018","unstructured":"Beurmanjer H, Kamal RM, de Jong CAJ, Dijkstra BAG, Schellekens AFA. Baclofen to prevent relapse in gamma-hydroxybutyrate (GHB)-dependent patients: a multicentre, open-label, non-randomized, controlled trial. CNS Drugs. 2018;32(5):437\u201342.","journal-title":"CNS Drugs"},{"issue":"1","key":"730_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s13063-016-1593-9","volume":"17","author":"A Lingford-Hughes","year":"2016","unstructured":"Lingford-Hughes A, Patel Y, Bowden-Jones O, Crawford MJ, Dargan PI, Gordon F, et al. Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial. Trials. 2016;17(1):472.","journal-title":"Trials."},{"issue":"1","key":"730_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-015-0471-4","volume":"15","author":"RM Kamal","year":"2015","unstructured":"Kamal RM, Schellekens A, De Jong CAJ, Dijkstra BAG. Baclofen as relapse prevention in the treatment of gamma-hydroxybutyrate (GHB) dependence: an open label study. BMC Psychiatry. 2015;15(1):1\u20138.","journal-title":"BMC Psychiatry."},{"issue":"1","key":"730_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1891\/rtnp.17.1.31.53169","volume":"17","author":"MJ Schuurmans","year":"2003","unstructured":"Schuurmans MJ, Shortridge-Baggett LM, Duursma SA. The Delirium Observation Screening Scale: a screening instrument for delirium. Res Theory Nurs Pract. 2003;17(1):31\u201350.","journal-title":"Res Theory Nurs Pract."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00730-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:47:02Z","timestamp":1618966022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00730-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00730-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"21 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The\u00a0Netherlands Ministry of Health, Welfare and Sports (VWS)\u00a0funded the collection of the Dutch data [316997] within the framework of the national programme of the Dutch Association of Mental Health and Addiction Care: \u2018Scoring results\u2019. They had no role in the execution of the project and interpretation of the results. The open access fee was paid by the Radboud University Nijmegen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Harmen Beurmanjer, Jurjen J. Luykx, Bieke De Wilde, Koen van Rompaey, Victor J.A. Buwalda, Cor A.J. De Jong, Boukje A.G. Dijkstra and Arnt F.A. Schellekens have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}